Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The Company is developing preclinical product candidates in oncology, and certain rare diseases, using its protocell technology. It also collaborates with partners to discover and develop additional product candidates. The Company is developing a series of orally active Chk1 inhibitors in collaboration with Sentinel Oncology Ltd. The Company is focusing its activities with protocells on the delivery of mini-circle DNA or mRNA to produce proteins intracellularly in specifically targeted organs or cells. It is collaborating with Adimab LLC for the discovery of antibodies against undisclosed immunotherapy targets in oncology.